-
公开(公告)号：US20190142922A1
公开(公告)日：2019-05-16
申请号：US16245378
申请日：2019-01-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20190127426A1
公开(公告)日：2019-05-02
申请号：US16208347
申请日：2018-12-03
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: C07K14/22 , A61K39/095
CPC classification number: C07K14/22 , A61K39/095 , A61K2039/55505 , A61K2039/58 , A61K2039/6037 , A61K2039/70
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
53.发明授权Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof 有权包含共轭荚膜糖抗原的免疫原性组合及其用途公开(公告)号：US09492559B2
公开(公告)日：2016-11-15
申请号：US14597488
申请日：2015-01-15
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
IPC: A61K39/00 , A61K39/02 , A61K39/09 , A61K39/385 , A61K47/48
CPC classification number: A61K47/4833 , A61K39/092 , A61K47/646 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。
-
54.发明申请GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF 审中-公开B组STR多糖聚糖 - 蛋白质结合体，生产结合物的方法，包含结合物的免疫组合物及其用途公开(公告)号：US20160324950A1
公开(公告)日：2016-11-10
申请号：US15144884
申请日：2016-05-03
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505 , A61K2039/55 , A61K2039/55505 , A61K2039/55566 , A61K2039/55577 , A61K2039/6037 , A61K2039/70 , C07K16/1275 , C07K16/44 , Y02A50/484
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
Abstract translation: 本发明涉及免疫原性多糖 - 蛋白质缀合物，其包含通常称为B族链球菌（GBS）的无乳链球菌的荚膜多糖（CP）和载体蛋白，其中CP选自血清型Ia，Ib ，II，III，IV，V，VI，VII，VIII和IX，并且其中CP具有大于约60％的唾液酸水平。 本发明还涉及制备缀合物和包含缀合物的免疫原性组合物的方法。 本发明还涉及包含多糖 - 蛋白质缀合物的免疫原性组合物，其中缀合物包含来自GBS血清型IV的CP和至少一种另外的血清型。 本发明还涉及使用本文公开的组合物在受试者中诱导免疫应答的方法，所述方法用于针对GBS和/或用于减少或预防受试者的侵袭性GBS疾病。 所得抗体可用于通过被动免疫治疗来治疗或预防GBS感染。
-
公开(公告)号：US08986710B2
公开(公告)日：2015-03-24
申请号：US13787594
申请日：2013-03-06
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: A61K39/095 , C07K14/22 , C07H21/04 , C07K16/12 , A61K39/00
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。
-
Patent Agency Ranking
56.发明申请公开(公告)号：US20150071959A1
公开(公告)日：2015-03-12
申请号：US14470922
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N7/00 , C12N2710/20034 , C12N2770/32634 , Y02A50/466
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
Abstract translation: 一方面，本发明涉及包含具有SEQ ID NO：1所示序列的第一多肽的组合物和具有SEQ ID NO：2所示序列的第二多肽。在一个实施方案中，组合物包含约120 μg/ ml的包含SEQ ID NO：1所示的氨基酸序列的第一多肽，120μg/ ml的包含SEQ ID NO：2所示的氨基酸序列的第二多肽，约2.8摩尔比的聚山梨醇酯-80 至第一多肽，约2.8摩尔比的聚山梨酯-80至第二多肽，约0.5mg / ml的铝，约10mM的组氨酸和约150mM的氯化钠。 在一个实施方案中，组合物的总剂量为约0.5ml。 在一个实施方案中，组合物的两剂量诱导针对人中不同异源亚家族A和亚科B菌株的杀菌效价。
-
公开(公告)号：US20250002875A1
公开(公告)日：2025-01-02
申请号：US18593348
申请日：2024-03-01
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
58.发明公开公开(公告)号：US20240216495A1
公开(公告)日：2024-07-04
申请号：US18446883
申请日：2023-08-09
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
CPC classification number: A61K39/08 , A61K9/19 , A61K2039/545
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US20230346903A1
公开(公告)日：2023-11-02
申请号：US18060779
申请日：2022-12-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , C07K16/1275 , C07K16/44 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20220401544A1
公开(公告)日：2022-12-22
申请号：US17764153
申请日：2020-09-24
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , John Lance Perez , Kathrin Ute Jansen , Paul Liberator , Cuiwen Tan , Thomas Richard Jones , Johannes Frederik Beeslaar , Judith Absalon , Jason Douglas Maguire , Shannon Lea Harris
IPC: A61K39/095 , A61P31/04 , A61K47/02
Abstract: NEW MATERIAL: Recombinant plasmid pTPGIF2 having a size of 4,660 base pairs and a structure obtained by inserting a DNA having a size of 52 base pairs and containing a sequence coding somatostatin into a BamHI incision site of a plasmid vector pTP70-1 capable or fusing a heteropeptide to a carboxy-terminal of a dihydrofolic acid reductase gene of E. coli. USE: Producton of fused protein containing somatostatin.
PREPARATION: A somatostatin gene is integrated into a plasmid vector pTP70-1. pTPGIF2 is kept in stable state when introduced into E. coli. C600 strain. The E. coli. C600 train containing pTPGIF2 is deposited in Fermentation Research institute as FERM BP-1577.
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.039 seconds)
